NIHR Performance Metrics - Delivering Clinical Research
Quarter 4 (2015 - 2016)

Research Ethics Committee Reference Number	Integrated Research Application	Name of Trial	Target Number Of Patients Agreed ?	Minimum Number Of	Maximum Number Of	Target Date To Recruit	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
11/YH/0140	69800	Luminous: Study to observe the effectiveness and safety of LUCENTIS(R) through individualised patient treatment and associated outcomes	Range Agreed	50	100	Not Available / Not Agreed		85	20/05/2015	Recruitment Finished
11/LO/1711	86867	An observational study of Avastin? (Bevacizumab) in combination with chemotherapy for treatment of first line metastatic colorectal adenocarcinoma.	Not Available / Not Agreed			Not Available / Not Agreed			02/04/2015	Recruitment Finished
12/WS/0300	114081	A Randomized, DoubleBlind, PlaceboControlled, ParallelGroup Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome-ODYSSEY OUTCOMES	Number Agreed	25	25	Not Available / Not Agreed		61	11/11/2015	Recruitment Finished
13/SC/0268	124775	An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment of pulmonary Pseudomonas aeruginosa in patients with cysti	Number Agreed	5	5	Not Available / Not Agreed		5	20/10/2015	Withdrawn By Sponsor
13/YH/0282	133239	Openlabel, Phase IIIb study to evaluate the efficacy and safety of subcutaneous (SC) Tocilizumab monotherapy or combination therapy with methotrexate (MTX) or other nonbiologic disease modifying antirheumatic drugs (DMARDs) in patients with severe Rheumat	Number Agreed	5	5	Not Available / Not Agreed		7	05/06/2015	Recruitment Finished
13/NW/0698	133706	A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK positive), stage IIIB or IV, non squamous nonsmall cell lung cancer (CLDK378A2301)	Number Agreed	2	2	Not Available / Not Agreed		7	15/04/2015	Recruitment Finished
13/LO/1245	1318223	A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects with Syndrome of Inappropriate Antidiuretic Hormone Secretion (O	Number Agreed	3	3	Not Available / Not Agreed		5	15/06/2015	Recruitment Finished
13/NW/0612	135524	A multicentre, randomised, doubleblind, parallel group, placebocontrolled, phase III efficacy and safety study of benralizumab (MEDI563) added to highdose inhaled corticosteroid plus longacting B2agnoist in patients with uncontrolled asthma (SIROCCO)	Number Agreed	1	1	Not Available / Not Agreed		3	20/05/2015	Recruitment Finished

13/YH/0389	142190	A 52 week, phase 3 double-blind, randomized, placebocontrolled, parallel-group study to assess the efficacy, safety and tolerability of pf-04950615 in subjects with heterozygous familial hypercholesterolemia (B1481021)	Number Agreed	6	6	Not Available / Not Agreed	6	02/02/2015	Recruitment Finished
14/NW/0130	149373	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	Number Agreed	5	5	Not Available / Not Agreed	17	26/10/2015	Recruitment Finished
14/WM/0170	154982	A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who w	Number Agreed	2	2	Not Available / Not Agreed	3	15/09/2015	Recruitment Finished
14/LO/1192	149876	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukaemia	Number Agreed	3	3	Not Available / Not Agreed	3	31/08/2015	Recruitment Finished
15/LO/0034	169816	OPuS-2: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE LEVELS OF BCX4161 FOR 12 WEEKS AS AN ORAL PROPHYLAXIS TREATMENT FOR ATTACKS OF HEREDITARY ANGIOEDEMA	Number Agreed	3	3	Not Available / Not Agreed	3	15/09/2015	Recruitment Finished
14/EE/1235	159181	A?PHASE?2?RANDOMIZED,?DOUBLE?BLIND?PLACEBO?CONTROLLED?TRIAL?OF?MHAA4549A,?A?MONOCLONAL?ANTIBODY,?IN?COMBINATION?WITH?OSELTAMIVIR?VERSUS?OSELTAMIVIR?FOR?TREATMENT?OF?SEVERE?INFLUENZA?A?INFECTION	Number Agreed	2	2	Not Available / Not Agreed	0	02/02/2016	Withdrawn By Host
14/NW/0119	148925	A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabapentin.	Number Agreed	10	10	Not Available / Not Agreed	0	16/03/2016	Withdrawn By Sponsor
14/SC/0033	146569	PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	6	6	Not Available / Not Agreed	5	26/01/2016	Recruitment Finished
15/SW/0197	181752	GO29432: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PDL1 ANTIBODY) COMPARED WITH GEMCITABINE+CISPLATIN OR CARBOPLATIN FOR PD-L1-SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCE	Number Agreed	4	4	Not Available / Not Agreed	0	19/04/2016	Recruitment Finished

13/WA/0080	120794	OBSERVATIONAL STUDY PROTOCOL IM101348ST LONGTERM EXPERIENCE WITH ABATACEPT SC IN ROUTINE CLINICAL PRACTICE STUDY	Number Agreed	6	6	Not Available / Not Agreed	6	20/04/2015	Recruitment Finished
14/NW/1257	161881	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 4 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Number Agreed	8	8	Not Available / Not Agreed	0	15/04/2015	Withdrawn By Sponsor
15/LO/0495	173451	TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 4 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE	Number Agreed	7	7	Not Available / Not Agreed	0	21/07/2015	Withdrawn By Sponsor
12/SC/0633	114037	CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)	Number Agreed	3	3	Not Available / Not Agreed	1	20/05/2015	Recruitment Finished
14/SC/0065	145868	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus	Number Agreed	8	8	Not Available / Not Agreed	5	15/03/2015	Recruitment Finished
14/NW/1053	157943	A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients with High Lipoprotein(a)	Number Agreed	3	3	Not Available / Not Agreed	3	17/06/2015	Recruitment Finished
15/LO/0032	148409	RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NA?VE ANAPLASTIC LYMPHOMA KINASE?POSITIVE ADVANCED NON? SMALL CELL LUNG CANCER	Number Agreed	2	2	Not Available / Not Agreed	1	08/12/2015	Recruitment Finished
14/LO/0324	146711	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin? in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 D	Number Agreed	3	3	Not Available / Not Agreed	1	06/01/2016	Recruitment Finished
15/LO/0967	178036	iNNOVATE Study: A randomized, double-blind, placebo-controlled, phase 3 study of ibrutinib or placebo in combination with Rituximab in Subjects with Waldenstroms Macroglobulinemia	Number Agreed	5	5	Not Available / Not Agreed	0	13/01/2016	Recruitment Finished